SAN DIEGO, CA--(Marketwire - Mar 29, 2012) - Medistem Inc. (PINKSHEETS: MEDS) announced today the appointment of Feng Lin, MD, Ph.D as Director of Chinese Operations. Dr. Lin has an extensive background in basic research and therapeutics development, having previously worked at the Hunan Medical University in both preclinical and clinical settings. Dr. Lin will be working out of Medistem's San Diego office.
"Medistem has been collaborating with the Hunan Medical University since 2007, including publishing the first clinical use of the ERC in 2009 (link to publication: http://www.translational-medicine.com/content/pdf/1479-5876-7-15.pdf)," stated Thomas Ichim, CEO of Medistem Inc. "Dr. Lin will coordinate our academic and business collaborations, including existing relationships with the Tongji Hospital of Wuhan, the Second Xiangya Hospital, of the Central South University, in Hunan, and our partnership with the Shanghai Jia Fu Medical Apparatus Inc. It is with great pleasure that we welcome Dr. Lin to the team."
Medistem is currently collaborating with the Shanghai Jia Fu Medical Apparatus Inc, a conglomerate that has commercialized cell therapies in China, for developing its "Universal Donor" stem cell product, the Endometrial Regenerative Cell (ERC), as a treatment for critical limb ischemia. The Shanghai Jia Fu Medical Apparatus company is currently utilizing patient's own bone marrow stem cells in the treatment of critical limb ischemia. The collaboration will assess whether superior results are obtained with the ERC. If results are successful, Medistem anticipates data collection and revenue generation within the next 18 months.
"To my knowledge Medistem is the only company to have taken a product from discovery in 2007 to an FDA cleared clinical trial within the short span of 4 years. It is my honor to work with such an aggressive team at opening up the Chinese Market," said Dr. Feng Lin. "A strong association between smoking and critical limb ischemia exists; at present China has more smokers than the population of the USA. We are excited about the possibility of a universal donor stem cell therapy for treatment of this condition that causes amputation in approximately 30% of patients within a year."
The ERC are a unique population of stem cells that originate from the endometrium and are derived from menstrual blood. One donor can generate 20,000 doses. To date ERCs have demonstrated the ability to produce more growth factors, and ability to generate new blood vessels, as compared to other stem cell types.
About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia and heart failure. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.